Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1502-12.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.